SEC Form 4 · accession 0001612571-26-000011
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert B Ford
Officer — CHAIRMAN AND CEO · Director
Period of report
Aug 25, 2026
Accepted (ET)
Aug 27, 2026 · 5:09 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000001800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common shares without par value | Aug 25, 2026 | M | 151,869 | $44.40 | A | 458,330 | D | |
| Common shares without par value | Aug 25, 2026 | M | 246,963 | $59.94 | A | 705,293 | D | |
| Common shares without par valueF1 | Aug 25, 2026 | S | 218,535 | $115.57 | D | 486,758 | D | |
| Common shares without par valueF2 | Aug 25, 2026 | S | 180,297 | $116.19 | D | 306,461 | D | |
| Common shares without par valueF3 | holding | — | — | — | 216,203 | I | Ford Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F4 | $44.40 | Aug 25, 2026 | M | 151,869 | D | Feb 17, 2020 | Feb 16, 2027 | Common Shares | 151,869 | 0 | D |
| Option (right to buy)F5 | $59.94 | Aug 25, 2026 | M | 246,963 | D | Feb 16, 2021 | Feb 15, 2028 | Common Shares | 246,963 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.
- F4Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
- F5Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.